Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 12, Décembre 2013
Page(s) 1131 - 1137
Section M/S Revues
DOI http://dx.doi.org/10.1051/medsci/20132912017
Publié en ligne 20 décembre 2013
  1. Carlson CB, Lawler J, Mosher DF. Structures of thrombospondins. Cell Mol Life Sci 2008 ; 65 : 672–686. [CrossRef] [PubMed]
  2. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000 ; 12 : 634–640. [CrossRef] [PubMed]
  3. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998 ; 93 : 1159–1170. [CrossRef] [PubMed]
  4. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990 ; 87 : 6624–6628. [CrossRef]
  5. Malek MH, Olfert IM. Global deletion of thrombospondin-1 increases cardiac and skeletal muscle capillarity and exercise capacity in mice. Exp Physiol 2009 ; 94 : 749–760. [CrossRef] [PubMed]
  6. Mirochnik Y, Kwiatek A, Volpert OV. Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets 2008 ; 9 : 851–862. [CrossRef] [PubMed]
  7. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001 ; 98 : 12485–12490. [CrossRef]
  8. Zhang X, Kazerounian S, Duquette M, et al. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. Faseb J 2009 ; 23 : 3368–3376. [CrossRef] [PubMed]
  9. Kaur S, Martin-Manso G, Pendrak ML, et al. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010 ; 285 : 38923–38932. [CrossRef] [PubMed]
  10. Smadja DM, d’Audigier C, Bieche I, et al. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol 2011 ; 31 : 551–559. [CrossRef] [PubMed]
  11. Xie HH, Zhou S, Chen DD, et al. GTP cyclohydrolase I/BH4 pathway protects EPCs via suppressing oxidative stress and thrombospondin-1 in salt-sensitive hypertension. Hypertension 2010 ; 56 : 1137–1144. [CrossRef] [PubMed]
  12. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 2009 ; 9 : 182–194. [CrossRef] [PubMed]
  13. Jin G, Tsuji K, Xing C, et al. CD47 gene knockout protects against transient focal cerebral ischemia in mice. Exp Neurol 2009 ; 217 : 165–170. [CrossRef] [PubMed]
  14. Brechot N, Gomez E, Bignon M, et al. Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice. PloS One 2008 ; 3 : e3950. [CrossRef] [PubMed]
  15. Masli S, Turpie B, Streilein JW. Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells. Int Immunol 2006 ; 18 : 689–699. [CrossRef] [PubMed]
  16. Grimbert P, Bouguermouh S, Baba N, et al. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation. J Immunol 2006 ; 177 : 3534–3541. [PubMed]
  17. Lamy L, Foussat A, Brown EJ, et al. Interactions between CD47 and thrombospondin reduce inflammation. J Immunol 2007 ; 178 : 5930–5939. [PubMed]
  18. Li Z, Calzada MJ, Sipes JM, et al. Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol 2002 ; 157 : 509–519. [CrossRef] [PubMed]
  19. Vallejo AN, Mugge LO, Klimiuk PA, et al. Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cells. J Immunol 2000 ; 164 : 2947–2954. [PubMed]
  20. Yamauchi Y, Kuroki M, Imakiire T, et al. Thrombospondin-1 differentially regulates release of IL-6 and IL-10 by human monocytic cell line U937. Biochem Biophys Res Commun 2002 ; 290 : 1551–1557. [CrossRef] [PubMed]
  21. Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 2002 ; 161 : 831–839. [CrossRef] [PubMed]
  22. Lanz TV, Ding Z, Ho PP, et al. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest 2010 ; 120 : 2782–2794. [CrossRef] [PubMed]
  23. Yang K, Vega JL, Hadzipasic M, et al. Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2009 ; 32 : 94–103. [CrossRef] [PubMed]
  24. Narizhneva NV, Razorenova OV, Podrez EA, et al. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. Faseb J 2005 ; 19 : 1158–1160. [PubMed]
  25. Martin-Manso G, Navarathna DH, Galli S, et al. Endogenous thrombospondin-1 regulates leukocyte recruitment, activation, accelerates death from systemic candidiasis. PloS One 2012 ; 7 : e48775. [CrossRef] [PubMed]
  26. McMaken S, Exline MC, Mehta P, et al. Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity. PloS One 2011 ; 6 : e19654. [CrossRef] [PubMed]
  27. Thakar CV, Zahedi K, Revelo MP, et al. Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest 2005 ; 115 : 3451–3459. [CrossRef] [PubMed]
  28. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001 ; 12 : 1434–1447. [PubMed]
  29. Bige N, Shweke N, Benhassine S, et al. Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. Kidney Int 2012 ; 81 : 1226–1238. [CrossRef] [PubMed]
  30. Kang DH, Anderson S, Kim YG, et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 2001 ; 37 : 601–611. [CrossRef] [PubMed]
  31. Wahab NA, Schaefer L, Weston BS, et al. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 2005 ; 48 : 2650–2660. [CrossRef] [PubMed]
  32. Hochegger K, Knight S, Hugo C, et al. Role of thrombospondin-1 in the autologous phase of an accelerated model of anti-glomerular basement membrane glomerulonephritis. Nephron 2004 ; 96 : e31–e38. [PubMed]
  33. Hugo C, Shankland SJ, Pichler RH, et al. Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int 1998 ; 53 : 302–311. [CrossRef] [PubMed]
  34. Rogers NM, Thomson AW, Isenberg JS. Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury. J Am Soc Nephrol 2012 ; 23 : 1538–1550. [CrossRef] [PubMed]
  35. Yung S, Lee CY, Zhang Q, et al. Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways. Nephrol Dial Transplant 2006 ; 21 : 1504–1513. [CrossRef] [PubMed]
  36. Naito T, Masaki T, Nikolic-Paterson DJ, et al. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol 2004 ; 286 : F278–F287.
  37. Hugo C, Pichler R, Meek R, et al. Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Kidney Int 1995 ; 48 : 1846–1856. [CrossRef] [PubMed]
  38. Han SH, Yang S, Jung DS, et al. Gene expression patterns in glucose-stimulated podocytes. Biochem Biophys Res Commun 2008 ; 370 : 514–518. [CrossRef] [PubMed]
  39. Sheibani N, Morrison ME, Gurel Z, et al. BIM deficiency differentially impacts the function of kidney endothelial and epithelial cells through modulation of their local microenvironment. Am J Physiol 2012 ; 302 : F809–F819.
  40. Daniel C, Wiede J, Krutzsch HC, et al. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 2004 ; 65 : 459–468. [CrossRef] [PubMed]
  41. Lu A, Miao M, Schoeb TR, et al. Blockade of TSP1-dependent TGF-beta activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol 2011 ; 178 : 2573–2586. [CrossRef] [PubMed]
  42. Xie XS, Li FY, Liu HC, et al. LSKL, a peptide antagonist of thrombospondin-1, attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction. Arch Pharmacal Res 2010 ; 33 : 275–284. [CrossRef]
  43. Daniel C, Takabatake Y, Mizui M, et al. Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol 2003 ; 163 : 1185–1192. [CrossRef] [PubMed]
  44. Daniel C, Schaub K, Amann K, et al. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes 2007 ; 56 : 2982–2989. [CrossRef] [PubMed]
  45. McGregor B, Colon S, Mutin M, et al. Thrombospondin in human glomerulopathies. A marker of inflammation and early fibrosis. Am J Pathol 1994 ; 144 : 1281–1287. [PubMed]